Latest news and press releases about Kalaris Therapeutics Inc (KLRS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Price
| Price | $3.18 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.31 |
| EV / EBITDA | -0.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -71.71% |
| Return on Invested Capital | -52.40% |
| Return on Assets | -44.47% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTV · CNTB · CNTX · IFRX · IMA · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of KLRS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks